K W Ter Horst1, K A van Galen1, P W Gilijamse1, A V Hartstra2, P F de Groot2, F M van der Valk2, M T Ackermans3, M Nieuwdorp2,4,5, J A Romijn6, M J Serlie1. 1. Department of Endocrinology and Metabolism, Academic Medical Center, Amsterdam, The Netherlands. 2. Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands. 3. Department of Clinical Chemistry, Laboratory of Endocrinology, Academic Medical Center, Amsterdam, The Netherlands. 4. Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands. 5. Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, The Netherlands. 6. Department of Medicine, Academic Medical Center, Amsterdam, The Netherlands.
Abstract
BACKGROUND/ OBJECTIVES: Insulin resistance of adipose tissue is an important feature of obesity-related metabolic disease. However, assessment of lipolysis in humans requires labor-intensive and expensive methods, and there is limited validation of simplified measurement methods. We aimed to validate simplified methods for the quantification of adipose tissue insulin resistance against the assessment of insulin sensitivity of lipolysis suppression during hyperinsulinemic-euglycemic clamp studies. SUBJECTS/ METHODS: We assessed the insulin-mediated suppression of lipolysis by tracer-dilution of [1,1,2,3,3-2H5]glycerol during hyperinsulinemic-euglycemic clamp studies in 125 overweight or obese adults (85 men, 40 women; age 50±11 years; body mass index 38±7 kg m-2). Seven indices of adipose tissue insulin resistance were validated against the reference measurement method. RESULTS: Low-dose insulin infusion resulted in suppression of the glycerol rate of appearance ranging from 4% (most resistant) to 85% (most sensitive), indicating a good range of adipose tissue insulin sensitivity in the study population. The reference method correlated with (1) insulin-mediated suppression of plasma glycerol concentrations (r=0.960, P<0.001), (2) suppression of plasma non-esterified fatty acid (NEFA) concentrations (r=0.899, P<0.001), (3) the Adipose tissue Insulin Resistance (Adipo-IR) index (fasting plasma insulin-NEFA product; r=-0.526, P<0.001), (4) the fasting plasma insulin-glycerol product (r=-0.467, P<0.001), (5) the Adipose Tissue Insulin Resistance Index (fasting plasma insulin-basal lipolysis product; r=0.460, P<0.001), (6) the Quantitative Insulin Sensitivity Check Index (QUICKI)-NEFA index (r=0.621, P<0.001), and (7) the QUICKI-glycerol index (r=0.671, P<0.001). Bland-Altman plots showed no systematic errors for the suppression indices but proportional errors for all fasting indices. Receiver-operator characteristic curves confirmed that all indices were able to detect adipose tissue insulin resistance (area under the curve ⩾0.801, P<0.001). CONCLUSIONS: Adipose tissue insulin sensitivity (that is, the antilipolytic action of insulin) can be reliably quantified in overweight and obese humans by simplified index methods. The sensitivity and specificity of the Adipo-IR index and the fasting plasma insulin-glycerol product, combined with their simplicity and acceptable agreement, suggest that these may be most useful in clinical practice.
BACKGROUND/ OBJECTIVES:Insulin resistance of adipose tissue is an important feature of obesity-related metabolic disease. However, assessment of lipolysis in humans requires labor-intensive and expensive methods, and there is limited validation of simplified measurement methods. We aimed to validate simplified methods for the quantification of adipose tissue insulin resistance against the assessment of insulin sensitivity of lipolysis suppression during hyperinsulinemic-euglycemic clamp studies. SUBJECTS/ METHODS: We assessed the insulin-mediated suppression of lipolysis by tracer-dilution of [1,1,2,3,3-2H5]glycerol during hyperinsulinemic-euglycemic clamp studies in 125 overweight or obese adults (85 men, 40 women; age 50±11 years; body mass index 38±7 kg m-2). Seven indices of adipose tissue insulin resistance were validated against the reference measurement method. RESULTS: Low-dose insulin infusion resulted in suppression of the glycerol rate of appearance ranging from 4% (most resistant) to 85% (most sensitive), indicating a good range of adipose tissue insulin sensitivity in the study population. The reference method correlated with (1) insulin-mediated suppression of plasma glycerol concentrations (r=0.960, P<0.001), (2) suppression of plasma non-esterified fatty acid (NEFA) concentrations (r=0.899, P<0.001), (3) the Adipose tissue Insulin Resistance (Adipo-IR) index (fasting plasma insulin-NEFA product; r=-0.526, P<0.001), (4) the fasting plasma insulin-glycerol product (r=-0.467, P<0.001), (5) the Adipose Tissue Insulin Resistance Index (fasting plasma insulin-basal lipolysis product; r=0.460, P<0.001), (6) the Quantitative Insulin Sensitivity Check Index (QUICKI)-NEFA index (r=0.621, P<0.001), and (7) the QUICKI-glycerol index (r=0.671, P<0.001). Bland-Altman plots showed no systematic errors for the suppression indices but proportional errors for all fasting indices. Receiver-operator characteristic curves confirmed that all indices were able to detect adipose tissue insulin resistance (area under the curve ⩾0.801, P<0.001). CONCLUSIONS: Adipose tissue insulin sensitivity (that is, the antilipolytic action of insulin) can be reliably quantified in overweight and obesehumans by simplified index methods. The sensitivity and specificity of the Adipo-IR index and the fasting plasma insulin-glycerol product, combined with their simplicity and acceptable agreement, suggest that these may be most useful in clinical practice.
Authors: Daniel F Vatner; Sachin K Majumdar; Naoki Kumashiro; Max C Petersen; Yasmeen Rahimi; Arijeet K Gattu; Mitchell Bears; João-Paulo G Camporez; Gary W Cline; Michael J Jurczak; Varman T Samuel; Gerald I Shulman Journal: Proc Natl Acad Sci U S A Date: 2015-01-06 Impact factor: 11.205
Authors: Kasper W Ter Horst; Pim W Gilijamse; Mariette T Ackermans; Maarten R Soeters; Max Nieuwdorp; Johannes A Romijn; Mireille J Serlie Journal: Metabolism Date: 2016-02-24 Impact factor: 8.694
Authors: O P Bachmann; D B Dahl; K Brechtel; J Machann; M Haap; T Maier; M Loviscach; M Stumvoll; C D Claussen; F Schick; H U Häring; S Jacob Journal: Diabetes Date: 2001-11 Impact factor: 9.461
Authors: M T Ackermans; A M Pereira Arias; P H Bisschop; E Endert; H P Sauerwein; J A Romijn Journal: J Clin Endocrinol Metab Date: 2001-05 Impact factor: 5.958
Authors: Filipe A Moura; Luiz Sergio F Carvalho; Riobaldo M R Cintra; Naiara V Martins; Valeria N Figueiredo; Jose C Quinaglia e Silva; Osorio L R Almeida; Otavio R Coelho; Andrei C Sposito Journal: Am J Physiol Endocrinol Metab Date: 2013-12-17 Impact factor: 4.310
Authors: Anthony T Virtue; Sam J McCright; Jasmine M Wright; Monica T Jimenez; Walter K Mowel; Jonathan J Kotzin; Leonel Joannas; Megha G Basavappa; Sean P Spencer; Megan L Clark; Stephen H Eisennagel; Adam Williams; Maayan Levy; Sasikanth Manne; Sarah E Henrickson; E John Wherry; Christoph A Thaiss; Eran Elinav; Jorge Henao-Mejia Journal: Sci Transl Med Date: 2019-06-12 Impact factor: 17.956
Authors: Joon Young Kim; Fida Bacha; Hala Tfayli; Sara F Michaliszyn; Shahwar Yousuf; Silva Arslanian Journal: Diabetes Care Date: 2018-11-19 Impact factor: 19.112
Authors: Kasper W Ter Horst; Daniel F Vatner; Dongyan Zhang; Gary W Cline; Mariette T Ackermans; Aart J Nederveen; Joanne Verheij; Ahmet Demirkiran; Bart A van Wagensveld; Geesje M Dallinga-Thie; Max Nieuwdorp; Johannes A Romijn; Gerald I Shulman; Mireille J Serlie Journal: Diabetes Care Date: 2020-12-08 Impact factor: 17.152